title: How to Summarize the Safety Profile of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy?
authors: Takahiro Hasegawa, Shionogi & Co, Ltd, Osaka, Japan; Hajime Uno, Dana-Farber Cancer Institute, Boston, MA; Lee-Jen Wei, Harvard University, Boston, MA.
authors: Takahiro
authors: T
authors: Hasegawa
authors: Takahiro Hasegawa, Shionogi & Co, Ltd, Osaka, Japan; Hajime Uno, Dana-Farber Cancer Institute, Boston, MA; Lee-Jen Wei, Harvard University, Boston, MA.
authors: Hajime
authors: H
authors: Uno
authors: Takahiro Hasegawa, Shionogi & Co, Ltd, Osaka, Japan; Hajime Uno, Dana-Farber Cancer Institute, Boston, MA; Lee-Jen Wei, Harvard University, Boston, MA.
authors: Lee-Jen
authors: LJ
authors: Wei
mesh_terms: D000740:Anemia; D001943:Breast Neoplasms; D000068817:Epoetin Alfa; D004921:Erythropoietin; D006397:Hematinics; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D009369:Neoplasms; D011788:Quality of Life; D011994:Recombinant Proteins; D059039:Standard of Care
chemical_list: D006397:Hematinics; D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa